MedTrace Logo

Iparomlimab and Tuvonralimab Combined With Chemotherapy and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

NCT07769853 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-08-18

No results posted yet for this study

Summary

This study aims to observe and evaluate the efficacy and safety of Iparomlimab and Tuvonralimab（QL-1706） combined with chemotherapy and bevacizumab ± radiotherapy as neoadjuvant therapy in patients with locally advanced rectal cancer, and to explore the value and implications of radiotherapy omission in this setting.

Conditions

  • Locally Advanced Rectal Cancer (LARC)
  • 5-12cm to Anal Verge

Interventions

DRUG

Iparomlimab and Tuvonralimab（QL-1706）combined with Chemotherapy and Bevacizumab

The QL1706 dosage is 5 mg/kg, administered via intravenous infusion once every 3 weeks, for a total of 4 doses, or until intolerable toxicity occurs or the subject withdraws informed consent. The bevacizumab injection dosage is 7.5 mg/kg, administered via intravenous infusion once every 3 weeks, for a total of 4 doses, or until intolerable toxicity occurs or the subject withdraws informed consent. Within 21 days after completing the 4th cycle of adjuvant treatment, the patient will be evaluated to determine whether additional radiotherapy would be required before surgery.

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2027-07-01
Completion
2029-12-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07769853 on ClinicalTrials.gov